177 related articles for article (PubMed ID: 19998405)
41. Photolabeling of tissue transglutaminase reveals the binding mode of potent cinnamoyl inhibitors.
Pardin C; Roy I; Chica RA; Bonneil E; Thibault P; Lubell WD; Pelletier JN; Keillor JW
Biochemistry; 2009 Apr; 48(15):3346-53. PubMed ID: 19271761
[TBL] [Abstract][Full Text] [Related]
42. Multifunctional nanocatalyst-based ultrasensitive detection of human tissue transglutaminase 2.
Huang Y; Li H; Fan Q; Wang L; Wang Y; Li G
Biosens Bioelectron; 2016 Sep; 83():85-90. PubMed ID: 27107144
[TBL] [Abstract][Full Text] [Related]
43. Amplification of transglutaminase 2 enhances tumor-promoting inflammation in gastric cancers.
Cho SY; Oh Y; Jeong EM; Park S; Lee D; Wang X; Zeng Q; Qin H; Hu F; Gong H; Liu X; Zhang G; Na D; Lee J; Chae J; Suh YS; Kong SH; Lee HJ; Kim JI; Park H; Zhang C; Yang HK; Lee C
Exp Mol Med; 2020 May; 52(5):854-864. PubMed ID: 32467608
[TBL] [Abstract][Full Text] [Related]
44. Transglutaminase 2 contributes to a TP53-induced autophagy program to prevent oncogenic transformation.
Yeo SY; Itahana Y; Guo AK; Han R; Iwamoto K; Nguyen HT; Bao Y; Kleiber K; Wu YJ; Bay BH; Voorhoeve M; Itahana K
Elife; 2016 Mar; 5():e07101. PubMed ID: 26956429
[TBL] [Abstract][Full Text] [Related]
45. Covalent blocking of fibril formation and aggregation of intracellular amyloidgenic proteins by transglutaminase-catalyzed intramolecular cross-linking.
Konno T; Morii T; Hirata A; Sato S; Oiki S; Ikura K
Biochemistry; 2005 Feb; 44(6):2072-9. PubMed ID: 15697232
[TBL] [Abstract][Full Text] [Related]
46. Transglutaminase 2 Regulates Self-renewal and Stem Cell Marker of Human Colorectal Cancer Stem Cells.
Kang S; Oh SC; Min BW; Lee DH
Anticancer Res; 2018 Feb; 38(2):787-794. PubMed ID: 29374703
[TBL] [Abstract][Full Text] [Related]
47. Tissue transglutaminase: an emerging target for therapy and imaging.
Pietsch M; Wodtke R; Pietzsch J; Löser R
Bioorg Med Chem Lett; 2013 Dec; 23(24):6528-43. PubMed ID: 24432384
[TBL] [Abstract][Full Text] [Related]
48. Protein crosslinking in assembly and remodelling of extracellular matrices: the role of transglutaminases.
Aeschlimann D; Thomazy V
Connect Tissue Res; 2000; 41(1):1-27. PubMed ID: 10826705
[TBL] [Abstract][Full Text] [Related]
49. Structural characterization of transglutaminase-catalyzed cross-linking between glyceraldehyde 3-phosphate dehydrogenase and polyglutamine repeats.
Ruoppolo M; Orrù S; Francese S; Caputo I; Esposito C
Protein Sci; 2003 Jan; 12(1):170-9. PubMed ID: 12493840
[TBL] [Abstract][Full Text] [Related]
50. Simultaneous analysis of enzyme structure and activity by kinetic capillary electrophoresis-MS.
Mironov GG; Clouthier CM; Akbar A; Keillor JW; Berezovski MV
Nat Chem Biol; 2016 Nov; 12(11):918-922. PubMed ID: 27595328
[TBL] [Abstract][Full Text] [Related]
51. Reaction profiling of a set of acrylamide-based human tissue transglutaminase inhibitors.
Jasim MH; Rathbone DL
J Mol Graph Model; 2018 Jan; 79():157-165. PubMed ID: 29179065
[TBL] [Abstract][Full Text] [Related]
52. GTP, an inhibitor of transglutaminases, is hydrolyzed by tissue-type transglutaminase (TGase 2) but not by epidermal-type transglutaminase (TGase 3).
Hitomi K; Ikura K; Maki M
Biosci Biotechnol Biochem; 2000 Mar; 64(3):657-9. PubMed ID: 10803976
[TBL] [Abstract][Full Text] [Related]
53. Transglutaminase-mediated crosslinking of a host defence peptide derived from human apolipoprotein B and its effect on the peptide antimicrobial activity.
Dell'Olmo E; Gaglione R; Arciello A; Piccoli R; Cafaro V; Di Maro A; Ragucci S; Porta R; Giosafatto CVL
Biochim Biophys Acta Gen Subj; 2021 Feb; 1865(2):129803. PubMed ID: 33249170
[TBL] [Abstract][Full Text] [Related]
54. TGM2 is a novel marker for prognosis and therapeutic target in colorectal cancer.
Miyoshi N; Ishii H; Mimori K; Tanaka F; Hitora T; Tei M; Sekimoto M; Doki Y; Mori M
Ann Surg Oncol; 2010 Apr; 17(4):967-72. PubMed ID: 20033322
[TBL] [Abstract][Full Text] [Related]
55. Targeted inactivation of Gh/tissue transglutaminase II.
Nanda N; Iismaa SE; Owens WA; Husain A; Mackay F; Graham RM
J Biol Chem; 2001 Jun; 276(23):20673-8. PubMed ID: 11274171
[TBL] [Abstract][Full Text] [Related]
56. HLA-DQ genotype and biochemical characterization of anti-transglutaminase 2 antibodies in patients with type 1 diabetes mellitus in Taiwan.
Lee YJ; Ting WH; Yang YW; Lin CJ; Hsieh YT; Huang CY; Lo FS; Chu CC; Lin CL; Lin WS; Lai TS
FASEB J; 2020 Jun; 34(6):8459-8474. PubMed ID: 32362042
[TBL] [Abstract][Full Text] [Related]
57. Monocytic Tissue Transglutaminase in a Rat Model for Reversible Acute Rejection and Chronic Renal Allograft Injury.
Zakrzewicz A; Atanasova S; Padberg W; Grau V
Mediators Inflamm; 2015; 2015():429653. PubMed ID: 26063971
[TBL] [Abstract][Full Text] [Related]
58. Aspirin inhibits glucose‑6‑phosphate dehydrogenase activity in HCT 116 cells through acetylation: Identification of aspirin-acetylated sites.
Ai G; Dachineni R; Kumar DR; Alfonso LF; Marimuthu S; Bhat GJ
Mol Med Rep; 2016 Aug; 14(2):1726-32. PubMed ID: 27356773
[TBL] [Abstract][Full Text] [Related]
59. Nuclear Magnetic Resonance Observation of α-Synuclein Membrane Interaction by Monitoring the Acetylation Reactivity of Its Lysine Side Chains.
Lee JH; Ying J; Bax A
Biochemistry; 2016 Sep; 55(35):4949-59. PubMed ID: 27455358
[TBL] [Abstract][Full Text] [Related]
60. A tertiary twist to the transglutaminase tale.
Koning F
PLoS Biol; 2007 Dec; 5(12):e337. PubMed ID: 18162046
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
